Aileron Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 15
- Market Cap
- $52.4M
- Website
- http://www.aileronrx.com
Clinical Trials
11
Active:4
Completed:5
Trial Phases
1 Phases
Phase 1:9
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (100.0%)A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Phase 1
Terminated
- Conditions
- Prevention of Chemotherapy-induced Myelosuppression
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05622058
- Locations
- 🇺🇸
Oncology and Hematology Associates of West Broward, Tamarac, Florida, United States
🇺🇸Southern Oncology Specialists, Huntersville, North Carolina, United States
🇺🇸Regional Medical Oncolgy Center, Wilson, North Carolina, United States
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Phase 1
Terminated
- Conditions
- Small-cell Lung CancerNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04022876
- Locations
- 🇺🇸
Arizona Cancer Center, Kingman, Arizona, United States
🇺🇸Mount Sinai Cancer Research Program, Miami, Florida, United States
🇺🇸Oncology & Hematology Associates of West Broward, Tamarac, Florida, United States
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: ALRN-6924 in combination with cytarabine
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02909972
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT02264613
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
Phase 1
Completed
- Conditions
- Growth Hormone Deficiency
- Interventions
- Drug: ALRN-5281 0.15 mg/kgDrug: ALRN-5281 0.015 mg/kgDrug: ALRN-5281 0.05 mg/kgDrug: Placebo 0.015 mg/kgDrug: Placebo 0.05mg/kgDrug: Placebo 0.15mg/kg
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT01775358
- Locations
- 🇺🇸
Vince and Associates Clinical Research, LLC, Overland Park, Kansas, United States
News
No news found